The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000882325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/07/2026
Date registered
Help: Date registered
17/07/2026
Date last updated
Help: Date last updated
17/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
The LEAP Study: Longitudinal Effects of protein beverage and Activity on muscular Performance in physically inactive older adults.
Scientific title
The LEAP Study: Longitudinal Effects of protein beverage supplementation and physical Activity on muscular Performance in physically inactive older adults.
Additional trial identifiers [1] 317610 0
Nil
Universal Trial Number (UTN)
Trial acronym
LEAP
Related trial records

Health condition
Health condition(s) studied:
Reduced muscular performance associated with ageing 342410 0
Condition category
Condition code
Musculoskeletal 338545 338545 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This trial will include two intervention groups. Participants in both groups will complete the same 12-week structured resistance training exercise program, with the beverage intervention differing between groups.

Group 1: Multi-ingredient high-protein beverage combined with resistance training
Participants allocated to Group 1 will receive a daily multi-ingredient high-protein beverage intervention in combination with the structured resistance training exercise program.

The multi-ingredient high-protein beverage was formulated in collaboration with an Australian food company at its Development and Innovation production facility. The beverage contains 10% protein derived from a blend of dairy- and plant-based protein sources, in addition to essential vitamins and minerals.

Intervention dose (250 mL/day):
Energy: 926 kJ
Flavour: Chocolate

Group 2: Low-protein beverage combined with resistance training
Participants allocated to Group 2 will receive a daily low-protein beverage intervention in combination with the same structured resistance training exercise program.

The low-protein beverage is commercially available and contains a lower protein composition (0.6%).

Intervention dose (250 mL/day):
Energy: 425 kJ
Flavour: Chocolate

Beverage Intervention Protocol
Participants will consume 250 mL of their allocated beverage (either the multi-ingredient high-protein beverage or the low-protein beverage) once daily for 12 weeks. The beverage will be consumed between meals, without intentional modification to participants’ habitual dietary intake.

Both beverages are ready-to-drink products. Participants will be instructed to consume the entire 250 mL dose at a time of their choosing during the day as a snack between meals. The beverage may be consumed at any time throughout the day; however, only one 250 mL dose will be consumed daily.

Adherence to the beverage intervention will be monitored using participant-completed daily intake questionnaires and verified through the weekly return of used beverage packaging.

Resistance Training Exercise Intervention
All participants will complete a 12-week resistance training exercise program conducted at a public gym facility. Exercise sessions will be performed twice weekly on non-consecutive days, with each session lasting approximately 40 minutes.

The first two exercise sessions will be supervised by an Accredited Exercise Physiologist to familiarise participants with the exercise protocol, ensure correct exercise technique, and promote safe participation. Following this familiarisation period, participants will independently continue the exercise program developed by the Exercise Physiologist using either an exercise program booklet or a mobile phone-based application.

The resistance training program will include a warm-up, resistance exercises targeting major upper and lower body muscle groups, and a cool-down. The exercise program will consist of:

Upper body exercises:
Lateral pulldown
Chest press

Lower body exercises:
Leg press
Hamstring curl
Knee extension

The 12-week resistance training program will be structured into four progressive phases:

Weeks 1–3: Foundation phase
2 sets per exercise
6–8 repetitions per set
Target RPE: 4–6 (CR10 scale)

Weeks 4–6: Build phase
2 sets per exercise
6–8 repetitions per set
Target RPE: 6–8 (CR10 scale)

Weeks 7–9: Power phase
3 sets per exercise
8 repetitions per set
Target RPE: 6–8 (CR10 scale)

Weeks 10–12: Peak phase
3 sets per exercise
8 repetitions per set
Target RPE: 6–8 (CR10 scale)

Resistance training loads will progressively increase throughout the intervention period. Load progression will involve an approximately 2% increase for upper-body strength exercises and a 10% increase for lower-body strength exercises. Adjustments to training loads will be determined based on participants’ perceived exertion following completion of each training phase to ensure appropriate progression of exercise intensity.

Participants will be familiarised with the CR10 Rating of Perceived Exertion (RPE) scale and the target RPE required following each exercise session. During the final week of each training phase, the Principal Investigator will review participants’ reported RPE to confirm adherence to the prescribed training intensity and progressive loading protocol.

Adherence to the exercise intervention will be assessed through gym attendance records, based on participant sign-in records collected at each exercise session.
Intervention code [1] 334462 0
Prevention
Intervention code [2] 334463 0
Lifestyle
Description of the comparator or control
The comparator is the group receiving the low-protein beverage in combination with the resistance training exercise intervention.

Group 2: Low-protein beverage combined with resistance training
Participants allocated to Group 2 will receive a daily low-protein beverage intervention in combination with the same structured resistance training exercise program.

The low-protein beverage is commercially available and contains a lower protein composition (0.6%).

Intervention dose (250 mL/day):
Energy: 425 kJ
Flavour: Chocolate

Beverage name: So Good Chocolate Almond Milk
Control group
Dose comparison

Outcomes
Primary outcome [1] 345820 0
Feasibility of the nutritional intervention (composite outcome)
Timepoint [1] 345820 0
Weekly throughout the trial.
Primary outcome [2] 345824 0
Feasibility of the exercise intervention
Timepoint [2] 345824 0
Weekly throughout the trial.
Primary outcome [3] 345825 0
Beverage acceptability (composite outcome)
Timepoint [3] 345825 0
Baseline, week 6 and week 12 (post-intervention)
Secondary outcome [1] 463417 0
Appendicular muscle mass
Timepoint [1] 463417 0
Baseline, week 12 (post-intervention)
Secondary outcome [2] 463418 0
Lower-body muscle strength
Timepoint [2] 463418 0
Baseline, week 12 (post-intervention)
Secondary outcome [3] 463421 0
Total dietary intake (composite outcome)
Timepoint [3] 463421 0
Baseline, week 12 (post-intervention)
Secondary outcome [4] 463422 0
Quality-of-Life
Timepoint [4] 463422 0
Baseline, week 6, week 12 (post intervention)
Secondary outcome [5] 464761 0
Upper-body muscle strength
Timepoint [5] 464761 0
Baseline, week 12 (post-intervention)
Secondary outcome [6] 464762 0
Primary outcome Physical performance (composite outcome)
Timepoint [6] 464762 0
Baseline, week 12 (post-intervention)

Eligibility
Key inclusion criteria
Aged 65 or over (no upper age limit)
Physically independent (perform everyday activities without needing physical assistance from others).
Have no medical condition that may impair their ability to safely perform exercise (liver, cardiovascular, pulmonary, renal or digestive diseases)
No food allergies
Have access to the internet
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Self-report dairy, soy, nut allergies
Self-report celiac disease or gluten intolerance
Self-report lactose intolerance
Have taken part in a nutrition or exercise clinical trial within the past six months
Are engaged in a resistance training program within the past three months (perform resistance training exercise sessions greater than or equal to 2x/week).
Are currently taking, or have taken within the past three months, any protein supplements consumed between meals (e.g. protein shakes) on a regular basis, typically containing more than 20g of protein/serving.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
After eligibility screening, trial participants will be assigned to one of the two intervention groups using block randomisation. Intervention groups will be assigned a code that does not reveal which intervention group it relates to. The key to the allocation code will be held by a person outside of the research team with no direct involvement with participant recruitment, intervention delivery, or outcome assessment during the trial.

The multi-ingredient high-protein beverage and low-protein beverage will be packaged in 1 L opaque bladder bags to ensure visual blinding. Each package will be labelled with all relevant allergen information, the date of production, and the coded identifier that will correspond to either the high-protein or low-protein beverage to maintain double-blinding of participants and the Principal Investigator. The allocation code will remain concealed until completion of the trial and finalisation of data analysis.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be allocated to study groups using computer-generated block randomisation using the appropriate Excel function.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Statistical analysis will be performed using SPSS (Statistical Package for the Social Sciences). A linear mixed-effects model will be used to analyse repeated measures data, with time, baseline value, group and time x group interaction as fixed effects and participants as a random effect. This approach allows simultaneous assessment of within-group change and between-group differences and accounts for intra-individual correlations and regression to the mean.
For all statistical analyses, significance will be set at p < 0.05.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 322163 0
Government body
Name [1] 322163 0
Commonwealth Government of Australia Industry Linked PhD Program
Country [1] 322163 0
Australia
Funding source category [2] 322306 0
Commercial sector/Industry
Name [2] 322306 0
Sanitarium, the Health Food Company
Country [2] 322306 0
Australia
Primary sponsor type
University
Name
Queensland University of Technology
Address
Country
Australia
Secondary sponsor category [1] 325227 0
Commercial sector/Industry
Name [1] 325227 0
Sanitarium, the Health Food Company
Address [1] 325227 0
Country [1] 325227 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320695 0
Queensland University of Technology University Human Research Ethics Committee
Ethics committee address [1] 320695 0
Ethics committee country [1] 320695 0
Australia
Date submitted for ethics approval [1] 320695 0
06/05/2026
Approval date [1] 320695 0
11/06/2026
Ethics approval number [1] 320695 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151310 0
Ms Lisa Arvieu
Address 151310 0
Faculty of Health - School of exercise and nutrition sciences - Queensland University of Technology, Kelvin Grove Campus, 4059 Kelvin Grove, Brisbane
Country 151310 0
Australia
Phone 151310 0
+61731387977
Fax 151310 0
Email 151310 0
Contact person for public queries
Name 151311 0
Prof. Jolieke van der Pols
Address 151311 0
Faculty of Health - School of exercise and nutrition sciences - Queensland University of Technology, Kelvin Grove Campus, 4059 Kelvin Grove, Brisbane
Country 151311 0
Australia
Phone 151311 0
+61731387977
Fax 151311 0
Email 151311 0
Contact person for scientific queries
Name 151312 0
Lisa Arvieu
Address 151312 0
Faculty of Health - School of exercise and nutrition sciences - Queensland University of Technology, Kelvin Grove Campus, 4059 Kelvin Grove, Brisbane
Country 151312 0
Australia
Phone 151312 0
+61731387977
Fax 151312 0
Email 151312 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.